Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04363853
PHASE2

Tocilizumab Treatment in Patients With COVID-19

Sponsor: Instituto Nacional de Cancerologia de Mexico

View on ClinicalTrials.gov

Summary

A phase II clinical trial will be carried out with the objective of studying the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection. Due to the high mortality of severe forms of SARS-CoV-2 and for ethical reasons, a control arm will not be included. Patients will be recruited by signing an informed consent and the baseline variables of interest will be recorded. Tocilizumab will be administered in one or two doses, depending on the case, and will be followed up for 30 days. The response to treatment, survival and evolution will be studied. Factors associated with improvement of ARDS and survival will be identified through multivariate analyzes. The results will be compared with those reported internationally.

Official title: Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2020-06-01

Completion Date

2027-12-31

Last Updated

2026-04-09

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Tocilizumab 20 MG/ML

We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.

Locations (1)

National Cancer Institute of Mexico

Mexico City, Mexico City, Mexico